MOLOGEN AG
MOLOGEN AG: Patient enrollment completed for IMPULSE study with immunotherapy MGN1703 in lung cancer (news with additional features)
DGAP-News: MOLOGEN AG / Key word(s): Study results/Study PRESS RELEASE N 17 / 2015 of 10/30/2015 MOLOGEN AG: Patient enrollment completed for IMPULSE study with immunotherapy MGN1703 in lung cancer The multinational randomized and controlled IMPULSE trial started at the end of March 2014 and evaluates the efficacy and safety of MGN1703 for the treatment of extensive disease small cell lung cancer. Primary endpoint is overall survival, the strongest possible endpoint that can be applied in cancer studies. Pre-defined biomarkers are used in this study and may help to identify those patients who will benefit the most from the treatment with MGN1703. In Germany, the trial is being conducted in collaboration with the “Aktion Bronchialkarzinom e.V.” (ABC group) – a renowned German oncologist’s network of lung cancer specialists. MOLOGEN plans to start the analysis by the end of 2016 and present results at the Annual Meeting of the American Society of Clinical Oncology 2017 (ASCO). “Lung cancer and especially small cell lung cancer is a cancer indication for which the benefit of standard treatment is currently very limited. We are pleased that we finalized patient enrolment within the timeframe envisaged and we are very excited to learn about the effect of MGN1703 in this disease”, said Dr. Matthias Schroff, CEO of MOLOGEN AG. The immunotherapy MGN1703 is currently investigated in three clinical trials. Further to the IMPULSE study, MGN1703 is being tested in the pivotal IMPALA study for first-line maintenance treatment of metastatic colorectal cancer (mCRC); recruitment for this trial is currently open. Furthermore, MGN1703 is also being investigated in phase I study in HIV (TEACH). The recruitment ended in September 2015 and topline results are expected in the first half of 2016. For more information on the trials IMPACT, IMPALA and TEACH please visit www.clinicaltrials.gov. IMPULSE small cell lung cancer study Small cell lung cancer (SCLC) In the US the estimated number of new lung cancer cases per year is around 230,000 (228,000) and in Europe more than 400,000 (410,000). The estimated number of deaths per year is around 160,000 in the US and more than 350,000 in Europe. The proportion of small cell lung cancer is approximately 15-20% of all lung cancer cases. When first diagnosed, approx. 60-80% of the SCLC-patients have already distant metastases or extensive local involvement. This advanced stage is called “extensive disease”. The prognosis for extensive disease SCLC is still very poor: median overall survival is less than 12 months and only few patients survive for more than two years. Thus, there is a high unmet medical need for new treatment options. ABC Group (“Aktion Bronchialkarzinom e.V.”) MGN1703 MOLOGEN AG The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and strong activation of the immune system. Due to this mechanism of action, MGN1703 has the potential to be applied to various indications. MGN1703 is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore it is also being investigated in a phase I study in HIV. MOLOGEN’s pipeline focus is on new innovative immunotherapies to treat diseases for which there is a high medical need. MOLOGEN AG is listed on the stock exchange and its headquarters are located in Berlin, Germany. Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
+++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=MEFLYUFDNA Document title: MOLOGEN AG: Patient enrollment completed for IMPULSE study with immunotherapy MGN1703 in lung cancer 2015-10-30 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News Service |
407319 2015-10-30 |